The U.S. Food and Drug Administration found that Johnson & Johnson’s single-dose Covid-19 vaccine was 66.1% effective in preventing moderate to severe virus disease and appeared safe.
The positive report on Wednesday represents a key step toward a possible FDA authorization of the vaccine as early as this weekend, according to a person familiar with the matter. J&J’s shot would be the third cleared for use in the U.S.